Teva Pharmaceuticals soars after Warren Buffett's Berkshire Hathaway discloses a stake (TEVA) | Markets Insider
FDA approves a generic version of Teva Pharmaceutical's best-selling drug; company shares tumble
13 Teva : Top 25 Pharma & BioPharma in 2018 - Contract Pharma
Israel's Teva to move US HQ from Pennsylvania to New Jersey | The Times of Israel
Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Industries Stock Is Believed To Be Modestly Undervalued
Teva: Great Investment With An Upside Even In Volatile Markets (NYSE:TEVA) | Seeking Alpha
Teva Execs Topped TASE's High Earners List for 2018 | Ctech
Award of Merit Manufacturing: TEVA Biologics Manufacturing Facility | 2018-10-16 | Engineering News-Record
Teva Pharmaceuticals to lay off 14,000 employees worldwide, 1,750 in Israel - The Jerusalem Post
Will Teva Stock Rebound After A 10% Fall In A Month?
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Patients Eagerly Awaited a Generic Drug. Then They Saw the Price. - The New York Times
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ANJL4AXVTBOMDKS2X4DIJZXZAY.jpg "Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters")
Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters
Teva launches generic EpiPen Jr. - Drug Delivery Business
Teva Announces New Brand Positioning and Visual Identity in North America
Teva Selling $3.5 Billion of Junk Bonds to Refinance Debt - Bloomberg
Teva recalls U.S.-made drugs following contamination fears | Pittsburgh Post-Gazette
Teva Narrows Losses in 2019 – Business News From Israel
Teva Migraine Drug Wins FDA Approval | Fortune
Teva down as it reports lower sales and profit for 2018
Teva Stock Dives As The Sales Downfall Continues For Its Biggest Product | Investor's Business Daily
Buffett's Berkshire adds to Teva stake in the first quarter
Teva Reports Fourth Quarter and Full Year 2019 Financial Results | Business Wire
Teva Pharmaceutical Industries Stock (TEVA): Why The Price Fell Today
